145 related articles for article (PubMed ID: 26030859)
1. Cervical cancer screening by human papillomavirus testing followed by cytology triage--reply.
Feldman S
JAMA Intern Med; 2015 Jun; 175(6):1068-9. PubMed ID: 26030859
[No Abstract] [Full Text] [Related]
2. Cervical cancer screening by human papillomavirus testing followed by cytology triage.
Giorgi-Rossi P; Arbyn M; Meijer CJ
JAMA Intern Med; 2015 Jun; 175(6):1068. PubMed ID: 26030858
[No Abstract] [Full Text] [Related]
3. Human papillomavirus testing for primary cervical cancer screening: is it time to abandon Papanicolaou testing?
Feldman S
JAMA Intern Med; 2014 Oct; 174(10):1539-40. PubMed ID: 25069413
[No Abstract] [Full Text] [Related]
4. Recommendations for Implementing Human Papillomavirus-Based Cervical Cancer Screening: Lessons Learned from the HPV FOCAL Trial.
Smith L; van Niekerk D; Coldman A; Krajden M; Franco EL; Ogilvie G
J Obstet Gynaecol Can; 2016 Aug; 38(8):723-6. PubMed ID: 27638983
[No Abstract] [Full Text] [Related]
5. [Precise screening, risk stratification: HPV and prevention of cervical cancer].
Lang J
Zhonghua Fu Chan Ke Za Zhi; 2014 Oct; 49(10):746-8. PubMed ID: 25537245
[No Abstract] [Full Text] [Related]
6. Cervical cancer screening in Switzerland: time to rethink the guidelines.
Vassilakos P; Catarino R; Frey Tirri B; Petignat P
Swiss Med Wkly; 2015; 145():w14112. PubMed ID: 25664576
[No Abstract] [Full Text] [Related]
7. Cervical cancer incidence in British Columbia: Predicting effects of changes from Pap to human papillomavirus screening and of changes in screening participation.
Coldman A; van Niekerk D; Smith L; Ogilvie G
J Med Screen; 2017 Dec; 24(4):195-200. PubMed ID: 27810984
[TBL] [Abstract][Full Text] [Related]
8. Re: Human papillomavirus testing in the prevention of cervical cancer.
Suba EJ; Michelow PM; Raab SS
J Natl Cancer Inst; 2011 Oct; 103(19):1482-3; author reply 1483-4. PubMed ID: 21859986
[No Abstract] [Full Text] [Related]
9. HPV-negative CIN3 and cervical cancer in Switzerland: any evidence of impact on screening policies?
Vassilakos P; Tran PL; Sahli R; Low N; Petignat P
Swiss Med Wkly; 2017; 147():w14559. PubMed ID: 29185245
[No Abstract] [Full Text] [Related]
10. [Human papillomavirus testing in cervical cancer screening at a public health service of Santiago, Chile].
Terrazas S; Ibáñez C; Lagos M; Poggi H; Brañes J; Barriga MI; Cartagena J; Núñez F; González F; Cook P; Van De Wyngard V; Ferreccio C
Rev Med Chil; 2015 Jan; 143(1):56-62. PubMed ID: 25860269
[TBL] [Abstract][Full Text] [Related]
11. High-risk human papillomavirus testing as a primary screening for cervical cancer: position statement by the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology.
Kong TW; Kim M; Kim YH; Kim YB; Kim J; Kim JW; Park MH; Park JH; Rhee JH; Lim MC; Hong JS
J Gynecol Oncol; 2020 Jan; 31(1):e31. PubMed ID: 31789003
[TBL] [Abstract][Full Text] [Related]
12. Should screening for cervical cancer go to primary human papillomavirus testing and eliminate cytology?
Swid MA; Monaco SE
Mod Pathol; 2022 Jul; 35(7):858-864. PubMed ID: 35256738
[TBL] [Abstract][Full Text] [Related]
13. [New guidelines for prevention of cervix cancer. ARG report on investigation and treatment of abnormal cytological smears].
Strander B; Elfgren K; Andrae B
Lakartidningen; 2011 Mar 9-15; 108(10):533-5. PubMed ID: 21744553
[No Abstract] [Full Text] [Related]
14. The renewal of the National Cervical Screening Program.
Carter J
Med J Aust; 2016 Oct; 205(8):357-358. PubMed ID: 27736622
[No Abstract] [Full Text] [Related]
15. [Early detection of cervical cancer in Chile: time for change].
Léniz Martelli J; Van De Wyngard V; Lagos M; Barriga MI; Puschel Illanes K; Ferreccio Readi C
Rev Med Chil; 2014 Aug; 142(8):1047-55. PubMed ID: 25424677
[TBL] [Abstract][Full Text] [Related]
16. The potential harms of primary human papillomavirus screening in over-screened women: a microsimulation study.
Naber SK; de Kok IM; Matthijsse SM; van Ballegooijen M
Cancer Causes Control; 2016 Apr; 27(4):569-81. PubMed ID: 26970740
[TBL] [Abstract][Full Text] [Related]
17. Cervical cancer: what is the optimal age for routine testing?
Rob L; Tachezy R; Robova H
Future Oncol; 2015; 11(8):1137-40. PubMed ID: 25832869
[No Abstract] [Full Text] [Related]
18. Genotyping for Human Papillomavirus (HPV) 16/18/52/58 Has a Higher Performance than HPV16/18 Genotyping in Triaging Women with Positive High-risk HPV Test in Northern Thailand.
Khunamornpong S; Settakorn J; Sukpan K; Suprasert P; Srisomboon J; Intaraphet S; Siriaunkgul S
PLoS One; 2016; 11(6):e0158184. PubMed ID: 27336913
[TBL] [Abstract][Full Text] [Related]
19. Incorporating human papillomavirus testing into cytological screening in the era of prophylactic vaccines.
Almonte M; Sasieni P; Cuzick J
Best Pract Res Clin Obstet Gynaecol; 2011 Oct; 25(5):617-29. PubMed ID: 21683657
[TBL] [Abstract][Full Text] [Related]
20. Urine-based HPV testing as a method to screen for cervical cancer.
Fontenot HB
Nurs Womens Health; 2015; 19(1):59-65. PubMed ID: 25690816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
